This association of HDAC6 with amyloid pathology may indicate that the use of agents targeting this enzyme may lead to a more effective reduction of β-amyloid plaques and soluble toxic Aβ-oligomers in the brain of patients with Alzheimer’s disease. The gene discussed is HDAC6; the disease is Alzheimer disease.